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Abstract A 68-year-old man was referred to the emergency
department 6 h after onset of sudden acute dyspnoea.
Immediate ECG showed sinus tachycardia with the typical
S1-Q3-T3 pattern and incomplete right bundle branch block.
Theechocardiogramshowedthepresenceofmobilethrombus
in the right atrium, a distended right ventricle with free wall
hypokinesia and displacement of the interventricular septum
towards the left ventricle. Lung spiral computed tomography
(CT) showed bilateral pulmonary involvement and confirmed
thepictureofathromboticsystemintherightatriumandcaval
vein. Thrombolytic treatment with recombinant tissue plas-
minogen activator (rt-PA) and heparin (alteplase 10 mg bolus,
then 90 mg over 2 h) was administered. Six hours after
thrombolysis bleeding gums and significant reduction in
platelet count (around 50,000) were observed. Heparin
was discontinued and bivalirudin (0.1 mg/kg bolus and
1.75 mg/kg per h infusion) plus warfarin was initiated and
continued for 5 days until the international normalised ratio
(INR) was within the therapeutic range (2.0–3.0) for 2
consecutive days, with concomitant platelet count normal-
isation. Lung spiral and lower abdominal CT beforedischarge
did not showthe presence ofclots inthe pulmonary arteriesof
the right and left lung. This case suggests that bivalirudin
could offer promise for use in patients with heparin-induced
thrombocytopaenia (HIT) after thrombolysis for massive
pulmonary embolism.
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Introduction
Massive pulmonary embolism (MPE) is a potentially fatal
event characterised by shock and/or hypotension (systolic
blood pressure < 90 mmHg or a reduction of > 40 mmHg
for 15 min that is not caused by new-onset arrhythmia,
hypovolaemia or sepsis) [1]. The recently published
European Society of Cardiology (ESC) guidelines on this
topic suggest that absolute indications for thrombolysis are
MPE with persistent hypotension or shock [2], and other
recent clinical practice guidelines of the American College
of Chest Physicians (ACCP) [3] confirm that thrombolytic
therapy is the first-line intervention in people with high-risk
pulmonary embolism and cardiogenic shock and/or arterial
hypotension. Heparin treatment is initiated during throm-
bolysis and continued for at least 5–6 days in combination
with oral anticoagulation until the international normalised
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DOI 10.1007/s12245-010-0193-9ratio (INR) is within the therapeutic range (2.0–3.0) for 2
consecutive days. Unfortunately, heparin-induced thrombo-
cytopaenia (HIT) can occur. We present here the case of a
patient with MPE which was successfully thrombolysed
and who developed an early type 2 HIT 6 h after heparin
infusion, which probably could be attributed to the use of
low molecular weight heparin (LMWH) in the previous
months. To avoid coagulation rebound after heparin discon-
tinuation, bivalirudin infusion in combination with oral
anticoagulation (vitamin K antagonists) was initiated and
continued until the INR was within the therapeutic range.
Case report
A 68-year-old man (174 cm, 95 kg) was referred to the
emergency department of our hospital 6 h after onset of
sudden acute dyspnoea. There was a history of previous
cardiovascular diseases, trauma and prostate cancer. Two
months before, the patient had been subjected to surgical
intervention for fracture of the right femur as a result of
accidental trauma. The surgery went well, and the patient
was treated with subcutaneous LMWH (enoxaparin) twice
daily for 15 days. On admission the patient was dyspnoeic,
cyanotic, haemodynamically unstable, hypotensive (80/
50 mmHg) and tachycardic (136 bpm), with low oxygen
saturation (82%) in oxygen with Venturi mask (6 l/min),
respiratory rate 30 breaths/min, and with primary hypoxemia
and metabolic acidosis (pH 7.30, pO2 54 mmHg, pCO2
23 mmHg, HCO3 16.2 mmol/l). Immediate ECG showed
sinus tachycardia with the typical S1-Q3-T3 pattern and
incomplete right bundle branch block (RBBB). Plasma
samples were obtained to check laboratory parameters
including troponin I, prothrombin time, activated partial
thromboplastin time (APTT),I N R ,f i b r i nd e g r a d a t i o n
products, D-dimers, and fibrinogen and N-terminal pro-
brain natriuretic peptide (NT-pro-BNP) plasma levels which
w e r em e a s u r e de v e r y6hf o rt h ef i r s t2 4ht h e ne v e r y1 2h
until clinical stabilisation and every 24 h subsequently. The
echocardiogram performed immediately on admission
showed the presence of mobile thrombus in the right atrium
(Fig. 1) and also showed a normally contracting left
ventricle, a distended right ventricle with free wall hypo-
kinesia and displacement of the interventricular septum
towards the left ventricle. In addition, an important tricuspid
regurgitation and inferior caval vein dilatation were present.
The spiral computed tomography (CT) showed bilateral
pulmonary involvement more prevalent on the right and
confirmed the picture of a thrombotic system in the right
atrium and caval vein. In the absence of contraindications
and after informing the patient thrombolysis was given
(alteplase 10 mg bolus, then 90 mg over 2 h) followed by
heparin according to APTT [3]. Arterial blood gas evaluation
was also performed every 30 min after thrombolytic
treatment, and then every 6 h up to stabilisation. We
observed an improvement in oxygen saturation (>90%), an
increase in blood pressure, a reduction in heart rate, complete
absence of cyanosis and a reduction in dyspnoea 30 min
after thrombolysis. The patient continued to receive heparin
treatment (1,000 U/h and/or according to APTT) and oxygen
delivered through a Venturi mask at a rate of 6 l/min.
Echocardiography performed 6 and 12 h after thrombolysis
showed a normal left ventricle with an ejection fraction of
65%andalessdistendedrightventricleandthedisappearance
of thrombi formation in the right atrium. Unfortunately, 6 h
after thrombolysis a significant reduction in platelet count
(around 50,000/ml) was observed (baseline 182,000/ml). In
addition, 3 h after thrombolysis moderate bleeding gums
(anterior and lateral) were also observed and these bleeding
gumsceasedcompletely2hafterheparindiscontinuation.The
observed HIT raised the question of whether to continue the
heparin or change the therapeutic strategy. We decided to
discontinue heparin and to start infusion of bivalirudin in
combination with oral anticoagulation (vitamin K antago-
nists). The bivalirudin was administered at a dose of
0.1 mg/kg bolus and 1.75 mg/kg per h infusion with dose
Fig. 1 a Echocardiogram at
entry: the arrow indicates the
presence of mobile thrombus
in the right atrium. b Spiral
computed tomography: the
arrows show bilateral
pulmonary involvement is
more prevalent on the right
and confirmed the picture of a
thrombotic system in the right
atrium and caval vein
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controlledevery6hforthe subsequentdaysuntilthe INRwas
within the therapeutic range (2.0–3.0) for 2 consecutive days.
Platelets increased progressively in the subsequent days and a
count ofaround200,000/mlwas observed3daysafter and the
values were always in the normal range during hospitalisation
and after discharge. In the subsequent days (2 days), Doppler
echocardiography of the inferior limbs revealed deep throm-
bosis in the left femoral–popliteal veins. On days 4 and 5 an
INR >2.0 was obtained and bivalirudin was discontinued
(5 days), and only oral anticoagulation was maintained. Lung
spiral CT, lower abdominal CT and Doppler echocardiogra-
phy of the inferior limbs were repeated before discharge
(9 days) and did not show the presence of clots in the
pulmonary arteries of the right and left lung and also showed
the disappearance of deep thrombosis in the left femoral–
popliteal veins. The patient was discharged after 10 days of
hospitalisationingoodcondition,withanINRof2.5–3.5with
indicationtocontinuewarfarintherapy.After 3months, a new
lung spiral CT and Doppler echocardiography of the inferior
limbs were performed and were negative for thrombotic
formations. Aventilation perfusion scan was also negative. In
the subsequent 6 months no episode of thrombosis recurred
andthe patient currently remains ingood healthand continues
to receive warfarin therapy.
Discussion
MPE can have potentially fatal consequences. Early
thrombolytic therapy in conjunction with heparin may be
life saving in MPE, especially if the patient is haemody-
namically unstable [4, 5], and the current indication
recommended for the use of thrombolytic therapy is MPE
with hypotension [1–3, 6]. The risks and costs of
thrombolysis also must be considered; bleeding is the most
common complication of thrombolysis. In addition, because
these patients also had to receive concomitant heparin, HIT
as a severe adverse effect of heparin therapy can occur. The
risk of this potentially fatal complication (mortality 8–20%)
depends on both the type of heparin used and the clinical
setting. The incidence is highest (3–5%) among patients
who have undergone orthopaedic surgery and received
unfractionated heparin. When HIT occurs the first step is to
discontinue heparin. The next step is to treat HIT using an
alternative type of anticoagulant. Even though the platelet
count is low, it is important to avoid platelet transfusions,
which can “add fuel to the fire” [3, 7]. Direct thrombin
inhibitors (DTI) are a class of anticoagulant medications
that do not cause HIT. Bivalirudin is the most recent DTI
to be introduced to the market, but it is currently FDA
approved with aspirin in patients with unstable angina
undergoing percutaneous transluminal coronary angioplasty.
Although most cases occur in patients receiving unfractio-
natedheparin,HITcanariseinvenousthrombosisprophylaxis
with an LMWH. We report a case of an early type 2 HIT in a
postoperativeorthopaedicpatientcomplicatedbydeepvenous
thrombosis and MPE, which was successfully treated with
thrombolysis but HIT developed in the early hours after
fibrinolysis, which probably could be attributed to the long
useofLMWHinthepreviousmonths(15days).Thisisonlya
hypothesisbecausenosensitisingtestwasperformed.Alsofor
this reason, we discontinued heparin infusion and to avoid
coagulation rebound, and bivalirudin infusion in combination
withwarfarinwas initiated and infusionmaintained for 5 days
without any side effects until an appropriate INR (2.0–3.0)
was obtained. We recognise that, also in Italy, bivalirudin is
not approved for HIT but the urgency of the case required a
quick decision which was submitted to the Ethics Committee,
which approved our choice. In conclusion, we report the
efficacy of the combination of bivalirudin infusion (5 days)
with warfarin when HIToccurs in the subsequent early hours
post-thrombolysis inMPE. Bivalirudin could offer promise as
an additional DTI for use in patients with HIT, but additional
studies need to be performed to further define its use.
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